Document:

Exhibit 10.1

 

AMENDMENT NO. 1 TO
 SERIES B-2 CONVERTIBLE PREFERRED STOCK

AND WARRANT PURCHASE AGREEMENT

 

This Amendment No. 1, dated as of March 28, 2014 (the “Amendment”), by and among Radius Health, Inc., a Delaware corporation (the “Corporation”), and the Series B-2 Majority Investors, amends that certain Series B-2 Convertible Preferred Stock and Warrant Purchase Agreement, dated February 14, 2014, by and among the Corporation and the Investors referenced therein (the “Agreement”). Capitalized terms used in this Amendment without definition shall have the same meaning as set forth in the Agreement unless otherwise indicated.

 

WHEREAS, the Agreement provides for the sale and issuance of shares of Series B-2 Preferred Stock at Subsequent Closings until March 15, 2014;

 

WHEREAS, the parties to this Amendment desire to amend the Agreement to extend the date for Subsequent Closings to April 18, 2014;

 

WHEREAS, pursuant to Section 17 of the Agreement, the Agreement may be amended by the written consent of the Corporation and the Series B-2 Majority Investors; and

 

WHEREAS, the parties hereto (other than the Corporation) constitute the Series B-2 Majority Investors.

 

NOW, THEREFORE, in consideration of the conditions and mutual covenants and agreements herein contained, the parties hereto, intending to be legally bound, hereby agree as follows:

 

SECTION 1.                Amendment to Section 4.2

 

The first sentence of Section 4.2 is hereby amended by deleting the date “March 15, 2014” referenced therein and replacing it with the date “April 18, 2014.”

 

SECTION 2.                Reaffirmation

 

The parties hereto hereby reaffirm all other provisions, commitments, obligations and agreements as set forth in the Agreement, except as specifically amended and modified herein, and confirm that the Agreement shall continue to be enforceable against the parties hereto in all respects. The Agreement and this Amendment shall be read and construed together as a single agreement and the term “Agreement” shall henceforth be deemed a reference to the Agreement as amended by this Amendment.

 

SECTION 3.                Prior Agreements

 

The Agreement, as amended by this Amendment, constitutes the entire agreement regarding and supersedes any prior understandings concerning the purchase and sale of the Series B-2 Preferred Stock.

 

SECTION 4.                Governing Law

 

This Amendment, and the rights of the parties hereto, shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, excluding choice of laws rules thereof.

 

1

 

SECTION 5.                Headings

 

Headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose.

 

SECTION 6.                Counterparts

 

This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument, and any of the parties hereto may execute this Amendment by signing any such counterpart.

 

[remainder of page intentionally left blank]

 

2

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

	
 
    	
RADIUS   HEALTH, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Robert E. Ward
    
	
 
    	
 
    	
Robert   E. Ward
    
	
 
    	
 
    	
President   and Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
 
    	
SERIES   B-2 MAJORITY INVESTORS:
    
	
 
    	
 
    
	
 
    	
F2   BIOSCIENCE IV L.P.
    
	
 
    	
By:   F2 Bioscience IV GP Ltd., General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Morana Jovan-Embiricos
    
	
 
    	
Name:
    	
Dr. Morana   Jovan-Embiricos
    
	
 
    	
Title:
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
F2   BIO VENTURES V L.P.
    
	
 
    	
By:   F2 Bio Ventures GP Ltd., General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Morana Jovan-Embiricos
    
	
 
    	
Name:
    	
Dr. Morana   Jovan-Embiricos
    
	
 
    	
Title:
    	
Authorized   Signatory
    
	
 
    	
 
    	
 
    
	
 
    	
BB   BIOTECH VENTURES II, L.P.
    
	
 
    	
By:
    	
BB   Biotech Ventures GP (Guernsey) Limited
    
	
 
    	
 
    	
As   General Partner to BB Biotech Ventures II, L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Ben Morgan
    
	
 
    	
Name:
    	
Ben   Morgan
    
	
 
    	
Title:
    	
Director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
BIOTECH   GROWTH N.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   H.J. van Neutegem
    
	
 
    	
Name:
    	
H.J.   van Neutegem
    
	
 
    	
Title:
    	
Managing   DirectorExhibit 10.2

 

CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 4 TO WORK STATEMENT NB-1

 

RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S entered into the certain Clinical Trial Services Agreement (“Agreement”) and that certain Work Statement NB-1 under the Agreement as of March 29, 2011 (“Effective Date”), and entered into an Amendment No. 1, Amendment No. 2, and Amendment No. 3 to Work Statement NB-1 as of December 9, 2011, June 18, 2012 and November 6, 2013 respectively, (as amended, “Work Statement NB-1”).

 

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 4 to Work Statement NB-1 (“Amendment No. 4”) effective as of March 28, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

 

NOW THEREFORE, in consideration of the mutual covenants and promises contained in this Amendment No. 3, the parties agree as follows:

 

1. Addition of Performance Incentive Bonus Program (a) In order to facilitate the timely completion of activities related to the Phase III clinical study of the subcutaneous injection form of abaloparatide (formerly, BA058) under Work Statement NB-1, Radius wishes to provide for an additional incentive payment of up to $5 million to NB.

 

(b) A new section at the bottom Attachment B to Work Statement NB-1 (Budgets, Fees, Pass-through Costs, and Payment Schedule*) is hereby amended to read in full as follows:

 

After the Amendment Date, NB shall receive an additional fee of $500,000 for every 50 subjects that complete End-of-Study visits and all procedures that are required to be performed according to the Schedule of Visits and Procedures as set out in Appendix 14.1 of the Protocol for the BA058-05-003 study (“Study Completers”), subject to a maximum payment amount of $5 million (the “Performance Incentive Bonus Program”).

 

(d) The “Payment Schedule” set forth in Attachment B to Work Statement NB-1 (Attachment 2 to the Agreement) is amended to add a new Paragraph (13) and Paragraph (14) immediately following Paragraph (12) of the Payment Schedule, which shall read in full as follows:

 

“(13)  In the event that an underwritten initial public offering of shares of Radius’ common stock (an “IPO”) is consummated prior to May 31, 2014, the purchase price for the Performance Incentive Bonus Program shall be paid solely in cash. Payments will be made by Radius upon submission of an invoice by NB for each group of 50 Study Completers until 450 subjects have completed and been invoiced under the Performance Incentive Bonus Program. The final payment of $500,000 for the last 50 Study Completers under the Performance Incentive Bonus Program will be due up the completion of the last study subject for BA058-05-003.

 

Should an IPO not be consummated by Radius prior to May 31, 2014, any payments due under the Performance Incentive Bonus Program shall be instead be paid in the form of Bonus Shares as part of the Bonus Equity Payment Amount in lieu of cash under the same model as for Work Statement NB-1, NB-2 and NB-3 under an amended Stock Issuance Agreement modeled on the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.”

 

2.  Ratification.  Except to the extent expressly amended by this Amendment No. 4, all of the terms, provisions and conditions of the Agreement and Work Statement NB-1 are hereby ratified and confirmed and shall remain in full force and effect.  The term “Work Statement NB-1”, as used in the Agreement, shall henceforth be deemed to be a reference to Work Statement NB-1 as amended by this Amendment No. 4.

 

3.  General.  This Amendment No. 4 may be executed in counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument

 

[remainder of this page intentionally left blank - signature page follows]

 

1

 

IN WITNESS WHEREOF the parties have caused this Amendment No. 4 to be executed by their respective duly authorized officers, and have duly delivered and executed this Amendment No. 4 under seal as of the Amendment Date.

 

 

	
RADIUS HEALTH, INC.
    	
NORDIC   BIOSCIENCE CLINICAL DEVELOPMENT VII A/S
    
	
 
    	
 
    
	
/s/ Robert E. Ward
    	
 
    	
/s/   Thomas Nielson
    
	
By:
    	
Robert E. Ward
    	
By:
    	
Thomas   Nielson
    
	
Title: 
    	
President and CEO
    	
Title:   
    	
CFO
    
	
 
    	
 
    
	
Notice Address
    	
Notice   Address
    
	
Radius Health, Inc.
    	
Nordic   Bioscience Clinical Development VII A/S
    
	
201 Broadway,   6th Floor
    	
Herlev   Hovedgade 207
    
	
Cambridge, MA   02139
    	
2730 Herlev
    
	
USA
    	
Denmark
    
	
Attn: President
    	
Attn:   Clinical Trial Leader &   Medical Advisor / Clinical Studies
    
	
Phone: 01.617.444.1834
    	
Phone:   45.4452.5251
    
	
Fax: 01.617.551.4701
    	
Fax:   45.4452.525

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]